Saniona AB (publ) SANION

Updated: 13 Sep 2026

Stockholm | Biotech | Biotechnology and drug development

No signal published yet

We already track Saniona and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Saniona free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
Stockholm
Type
Biotech
Sector
Biotechnology and drug development
We're already tracking Saniona AB (publ) — here are the latest events we've registered

Recent News

  • On August 27, 2026, Saniona published its Q2 2026 interim report, confirming cash and cash equivalents of SEK 486.3 million and two lead internal assets preparing for Phase 1 clinical entry around year-end. Additionally, on August 10, 2026, partner AstronauTx exercised its option to acquire global rights to the ATX0926 program, delivering USD 5 million in shares to Saniona.

What Firelda Watch includes for Saniona AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Saniona AB (publ) will be delivered in the same format.

Want to follow Saniona AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Saniona free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Saniona AB (publ) SANION
Saniona — follow and we'll monitor it
Follow Saniona free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.